TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 138 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $32,534,016 | -17.1% | 2,118,100 | +21.4% | 0.59% | -23.4% |
| Q1 2023 | $39,229,307 | +48.9% | 1,744,300 | +39.2% | 0.77% | +52.8% |
| Q4 2022 | $26,353,324 | -14.7% | 1,253,130 | 0.0% | 0.50% | -12.0% |
| Q3 2022 | $30,877,000 | +65.0% | 1,253,130 | +62.3% | 0.57% | +69.0% |
| Q2 2022 | $18,710,000 | +41.9% | 772,200 | +46.2% | 0.34% | +175.6% |
| Q1 2021 | $13,187,000 | – | 528,100 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |